Recruiting

Text Message Reminders

Sponsor:

University of Chicago

Code:

NCT06446661

Conditions

Acute Lymphoblastic Leukemia

T-cell Lymphoblastic Lymphoma

Eligibility Criteria

Sex: All

Age: 15+

Healthy Volunteers: Not accepted

Interventions

High Intensity

No Text Messagings

Low Intensity Text Messaging

Study Details

Brief summary:

This is a single center 2-phase study to assess effects of using text messages on adherence to oral chemotherapy for patients with acute lymphoblastic leukemia (ALL) or T-cell lymphoblastic lymphoma.

Conditions

Acute Lymphoblastic Leukemia

T-cell Lymphoblastic Lymphoma

Study ID

NCT06446661

Start date

May 19, 2026

Status verified date

Jul, 2026

Completion date

Jun 15, 2028

Anticipated

Primary completion date

Jun 15, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 15+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age of 15 years or older at time of enrollment
  • Diagnosed with ALL or T-cell lymphoblastic lymphoma
  • Currently receiving treatment with pediatric-based regimen that includes maintenance with mercaptopurine and methotrexate (e.g., CALGB 10403). Study participation begins with the start of maintenance, so enrollment occurs prior to the start of maintenance. Patients in the pilot phase may have already started maintenance as long as the end of their maintenance therapy is scheduled to occur after the end of the 28-day pilot intervention.

Exclusion Criteria:

  • Patient or caregiver who would receive text message reminders does not have a cell phone that receives text messages
  • Patient does not wish to participate
  • Text messages will be crafted in the patient's preferred language for medical communication, so English fluency is not an enrollment requirement.

Study Design

Enrollment

48 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Other

Interventions and Outcome Measures

Arms

active comparator: Efficacy Phase: High Intensity Messaging

Receives high-intensity text messaging for 2 cycles of treatment

active comparator: Efficacy Phase: Low Intensity Messaging

Receives no texts for 1st cycle and low-intensity texts for 2nd cycle

experimental: Pilot Phase Arm

Participants receive high-intensity text messaging for 28 days

Interventions

High Intensity

Daily texts

No Text Messagings

Standard Care

Low Intensity Text Messaging

Weekly Texts

Primary outcome measure

  • To compare adherence to oral chemotherapy between study groups for first treatment cycle (Efficacy Phase) [ Time Frame: 84 days after completion of enrollment to efficacy phase of study ]
  • Feasibility of text message interventions to improve adherence to oral chemotherapy (Pilot Phase) [ Time Frame: 28 days after completion of enrollment to pilot phase of study ]

Central Contacts and Locations

Central contacts

Clinical Trials Intake

1-855-702-8222cancerclinicaltrials@bsd.uchicago.edu

Locations

University of Chicago Medicine Comprehensive Cancer Center

Recruiting

Chicago, Illinois, United States, 60637

Contacts

Clinical Trials Intake

855-702-8222cancerclinicaltrials@bsd.uchicago.edu

Principal Investigator:

Austin Wesevich

More Information

Sponsor

University of Chicago

Last update posted

Jul 10, 2026

Last verified

Jul, 2026

Keywords

  • Oral Chemotherapy

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by University of Chicago on 2026-07-10.